Metastatic Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Metastatic Breast Cancer  Market Outlook

Thelansis’s “Metastatic Breast Cancer  Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Breast Cancer  treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Metastatic Breast Cancer  Overview

Breast cancer, particularly hormone receptor-positive (HR+) and HER2-negative (HER2-) subtypes, stands as the predominant malignancy affecting young women globally, constituting roughly 30% of new cancer diagnoses and accounting for 25% of cancer-related deaths. The prognosis and clinical trajectory of metastatic breast cancer patients are highly variable, influenced by diverse factors, including patient characteristics such as age and existing health conditions, as well as tumor attributes like hormone receptor status, tumor grade, and site of metastasis. Although the median survival period for metastatic breast cancer is typically 2-4 years, specific subgroups may experience extended survival, particularly those with less aggressive or localized metastatic disease. Initial diagnosis reveals metastatic spread in about 6%-10% of cases. Despite advancements in treatment strategies for metastatic breast cancer, the impact on overall survival remains modest. Presently, metastatic breast cancer is largely deemed incurable, with treatment primarily aimed at palliation. Nevertheless, the emergence of novel therapeutic agents has spurred efforts to prolong survival in this setting. Treatment protocols vary depending on the molecular subtype of breast cancer. HER2-positive patients typically receive trastuzumab in combination with pertuzumab and a taxane in the first-line setting, while trastuzumab emtansine is preferred in the second line. Hormone receptor-positive and HER2-negative patients are typically treated with hormone therapy alone or in combination with a CDK inhibitor, such as palbociclib, in the first line, and subsequent lines may include hormone therapy with or without a CDK4/6 inhibitor, irrespective of BRCA status. For triple-negative breast cancer (TNBC) patients with PD-L1 expression, atezolizumab combined with nab-paclitaxel has rapidly gained acceptance as the standard first-line therapy following its approval in August 2019. Taxane-based regimens are commonly employed for TNBC patients lacking PD-L1 expression.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Metastatic Breast Cancer  – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034